November 29, 2017 / 12:13 PM / 17 days ago

BRIEF-Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics

Nov 29 (Reuters) - Medicines Co:

* THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS

* MEDICINES - TO SELL INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS FOR $270 MILLION IN UPFRONT CONSIDERATION AND GUARANTEED PAYMENTS

* MEDICINES - DEAL INCLUDES TIERED ROYALTY PAYMENTS OF 5% TO 25% ON WORLDWIDE NET SALES OF VABOMERE, ORBACTIV AND MINOCIN IV, AMONG OTHER THINGS

* MEDICINES CO - MELINTA TO PAY DEAL CONSIDERATION, INCLUDING $165 MILLION IN CASH, PAID AT CLOSING, MELINTA SHARES WITH A MARKET OF $55 MILLION, AMONG OTHERS

* MEDICINES CO - ‍CONCURRENT WITH EXECUTION OF DEAL, CO RECEIVED BINDING COMMITMENT FROM DEERFIELD MANAGEMENT AFFILIATE

* MEDICINES CO - DEERFIELD MANAGEMENT ‍AFFILIATE COMMITTED TO PROVIDE FINANCING TO MELINTA IN CONNECTION WITH DEAL,TO PROVIDE A $100 MILLION CREDIT FACILITY​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below